Therapeutics
Search By Attributes
Search Results
| Name | Synonyms | FDA Status | Company | Target Type | Therapy Type | Approved For |
|---|---|---|---|---|---|---|
| ADEL-Y01 | Alzheimer's Disease (Phase 1) | ADEL, Inc., Oscotec Inc. | Tau | Immunotherapy (passive) | ||
| AL044 | Alzheimer's Disease (Phase 1) | Alector | Inflammation | Immunotherapy (passive) | ||
| ALIA-1758 | Alzheimer's Disease (Phase 1) | AbbVie, Aliada Therapeutics | Amyloid-Related | Immunotherapy (passive) | ||
| APNmAb005 | RAA7 | Alzheimer's Disease (Phase 1) | Aprinoia Therapeutics | Tau | Immunotherapy (passive) | |
| Bepranemab | UCB0107, UCB 0107, Antibody D |
Progressive Supranuclear Palsy (Phase 1), Alzheimer's Disease (Phase 2) | Hoffmann-La Roche, UCB S.A. | Tau | Immunotherapy (passive) | |
| IBC-Ab002 | Alzheimer's Disease (Phase 1) | ImmunoBrain Checkpoint | Amyloid-Related, Inflammation, Other | Immunotherapy (passive) | ||
| LU AF82422 | Parkinson's Disease (Phase 1), Multiple System Atrophy (Phase 2) | Genmab A/S, Lundbeck | alpha-synuclein | Immunotherapy (passive) | ||
| Lu AF87908 | hC10.2 | Alzheimer's Disease (Phase 1) | Lundbeck | Tau | Immunotherapy (passive) | |
| PMN310 | Alzheimer's Disease (Phase 1) | ProMIS Neurosciences, Inc. | Amyloid-Related | Immunotherapy (passive) | ||
| SAR446159 | ABL301, SynucleinxIGF1R mAb |
Parkinson's Disease (Phase 1) | ABL Bio, Inc., Sanofi | alpha-synuclein | Immunotherapy (passive) | |
| TAK-341 | MEDI1341 | Parkinson's Disease (Phase 1), Multiple System Atrophy (Phase 2) | AstraZeneca, Takeda Pharmaceutical Company | alpha-synuclein | Immunotherapy (passive) | |
| TB006 | Alzheimer's Disease (Phase 1) | TrueBinding, Inc. | Inflammation | Immunotherapy (passive) | ||
| THN391 | Alzheimer's Disease (Phase 1) | Therini Bio®, Inc. | Inflammation | Immunotherapy (passive) | ||
| UCB7853 | Parkinson's Disease (Phase 1) | UCB S.A. | alpha-synuclein | Immunotherapy (passive) | ||
| VHB937 | Alzheimer's Disease (Phase 1), Amyotrophic Lateral Sclerosis (Phase 2) | Novartis Pharmaceuticals Corporation | Amyloid-Related | Immunotherapy (passive) | ||
| VY-TAU01 | HC3LC2, Voyager_9, VY7523 |
Alzheimer's Disease (Phase 1) | Voyager Therapeutics | Tau | Immunotherapy (passive) |